<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Orphanet J Rare Dis</journal-id>
      <journal-id journal-id-type="iso-abbrev">Orphanet J Rare Dis</journal-id>
      <journal-title-group>
        <journal-title>Orphanet Journal of Rare Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1750-1172</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26076658</article-id>
      <article-id pub-id-type="pmc">4485869</article-id>
      <article-id pub-id-type="publisher-id">295</article-id>
      <article-id pub-id-type="doi">10.1186/s13023-015-0295-9</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Chronic myelomonocytic leukemia as a cause of fatal uncontrolled inflammation in familial Mediterranean fever</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Awad</surname>
            <given-names>Fawaz</given-names>
          </name>
          <address>
            <email>fawaz.awad@inserm.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Georgin-Lavialle</surname>
            <given-names>Sophie</given-names>
          </name>
          <address>
            <email>s.georgin.lavialle@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brignier</surname>
            <given-names>Anne</given-names>
          </name>
          <address>
            <email>anne.brignier@nck.aphp.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Derrieux</surname>
            <given-names>Coralie</given-names>
          </name>
          <address>
            <email>coralie.derrieux@nck.aphp.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aouba</surname>
            <given-names>Achille</given-names>
          </name>
          <address>
            <email>achille.aouba@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stankovic-Stojanovic</surname>
            <given-names>Katia</given-names>
          </name>
          <address>
            <email>katia.stankovic@tnn.aphp.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Grateau</surname>
            <given-names>Gilles</given-names>
          </name>
          <address>
            <email>gilles.grateau@tnn.aphp.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Amselem</surname>
            <given-names>Serge</given-names>
          </name>
          <address>
            <phone>+33 1 44 73 52 39</phone>
            <email>serge.amselem@inserm.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Hermine</surname>
            <given-names>Olivier</given-names>
          </name>
          <address>
            <phone>+33 1 44 49 52 83</phone>
            <email>ohermine@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Karabina</surname>
            <given-names>Sonia-Athina</given-names>
          </name>
          <address>
            <phone>+33 1 44 73 52 39</phone>
            <email>sonia.karabina@trs.aphp.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Sorbonne Universit&#xE9;s, UPMC University Paris 06, INSERM UMR_S933, H&#xF4;pital Armand-Trousseau, Paris, F-75012 France </aff>
        <aff id="Aff2"><label/>Centre de r&#xE9;f&#xE9;rence de la fi&#xE8;vre m&#xE9;diterran&#xE9;enne familiale, DHU I2B, Service de m&#xE9;decine interne, H&#xF4;pital Tenon, Assistance Publique-H&#xF4;pitaux de Paris (AP-HP), Paris, France </aff>
        <aff id="Aff3"><label/>Service d&#x2019;H&#xE9;matologie clinique, AP-HP, H&#xF4;pital Necker, Universit&#xE9; Paris Descartes &#x2013; Sorbonne Paris Cit&#xE9;, Imagine Institute, INSERM UMR 1163 et CNRS ERL 8254, Paris, France </aff>
        <aff id="Aff4"><label/>Laboratoire d&#x2019;h&#xE9;matologie biologique, H&#xF4;pital Necker, 149 rue de S&#xE8;vres, 75015 Paris, France </aff>
        <aff id="Aff5"><label/>Service de G&#xE9;n&#xE9;tique, Assistance Publique-H&#xF4;pitaux de Paris (AP-HP), H&#xF4;pital Trousseau, F-75012 Paris, France </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>16</day>
        <month>6</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>16</day>
        <month>6</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>10</volume>
      <elocation-id>76</elocation-id>
      <history>
        <date date-type="received">
          <day>25</day>
          <month>3</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>9</day>
          <month>6</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Awad et al. 2015</copyright-statement>
        <license license-type="open-access">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>We report on a familial Mediterranean fever (FMF) patient homozygous for p.M694V in the <italic>MEFV</italic> gene who developed chronic myelomonocytic leukemia (CMML) leading to an uncontrolled and fatal inflammatory syndrome. Plasma levels of IL-6 and IL-18 were found to be very high, as compared to healthy controls and CMML-free FMF patients.</p>
        <p>Our study unveils the interplay between two different disorders involving the same target cells, suggesting that in myelodysplasia with inflammatory manifestations, mutations in genes causing autoinflammatory syndromes, like <italic>MEFV</italic>, can be present and thus could be sought. Early chemotherapy with interleukin inhibitors could be proposed in such unusual situations.</p>
        <sec>
          <title>Electronic supplementary material</title>
          <p>The online version of this article (doi:10.1186/s13023-015-0295-9) contains supplementary material, which is available to authorized users.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>FMF</kwd>
        <kwd>
          <italic>MEFV</italic>
        </kwd>
        <kwd>Inflammation</kwd>
        <kwd>CMML</kwd>
        <kwd>Interleukin inhibitors</kwd>
        <kwd>Monocytes</kwd>
        <kwd>Interleukin 18</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Correspondence</title>
      <p>Letters to the Editor:</p>
      <p>Familial Mediterranean fever (FMF) is an autosomal recessive autoinflammatory disorder caused by mutations in the <italic>MEFV</italic> gene, mainly p.M694V in exon 10 [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. It is the commonest hereditary fever syndrome with recurrent episodes of fever accompanied by abdominal, chest and joint pain. <italic>MEFV</italic> encodes pyrin, a protein expressed in neutrophils and monocytes [<xref ref-type="bibr" rid="CR3">3</xref>] and is involved in the regulation of inflammation. Daily and life-long colchicine administration can prevent both attacks and occurrence of inflammatory amyloidosis. <italic>Ex-vivo</italic> studies performed with monocytes from FMF patients have demonstrated the importance of increased secretion of the potent pyrogenic cytokine interleukin (IL)-1&#x3B2;. Subsequently, IL-1 inhibitors have been proposed as alternative or supplementary treatment in colchicine-resistant patients or in those presenting adverse events [<xref ref-type="bibr" rid="CR4">4</xref>]. In addition, blocking the IL-1 pathway is safer, in terms of infectious risk, in comparison with other biological treatments [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p>
      <p>Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder classified as a myelodysplastic/myeloproliferative neoplasm [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. CMML is characterized by absolute monocytosis (&gt;1&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L) in peripheral blood persisting for at least 3 months [<xref ref-type="bibr" rid="CR8">8</xref>]. The median age of CMML diagnosis is 70 years [<xref ref-type="bibr" rid="CR7">7</xref>] and current treatment includes hydroxyurea and/or 5-azacitidine [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
      <p>We report a case of an 84-year-old man who had typical FMF since his childhood. The diagnosis of FMF was confirmed by identification in the <italic>MEFV</italic> gene of the M694V mutation in the homozygous state. Lifelong colchicine therapy (1 mg/day) for 40 years abolished febrile crises. No other medical problem was reported. At the age of 83 (t&#x2009;=&#x2009;0), he started complaining of general weakness and a blood test showed profound macrocytic anemia, with no other cytopenia (Hb&#x2009;=&#x2009;7.2 g/dL; MCV&#x2009;=&#x2009;104 fL; leukocytes 7.6&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L; platelets 228&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L). Additional laboratory tests showed no signs of hemolysis, inflammatory disease, hypothyroidism or deficiency in vitamin B12 or B9. Thus, a bone marrow smear was performed and revealed refractory anemia without blast excess (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a</xref>, I&amp;II) and with a normal karyotype. He received iterative red blood cell transfusions and vitamin D.<fig id="Fig1"><label>Fig. 1</label><caption><p>Morphological features of CMML in patient #9 and cytokine profiles in patients and controls. <bold>a</bold> Bone marrow smears from patient #9 with CMML and FMF (see Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1) (I) showing dysgranulopoiesis (hypogranular cytoplasm and D&#xF6;hle bodies indicated with the arrow) at t&#x2009;=&#x2009;0; (II) dysplastic binucleate erythroblasts at the stage of myelodysplastic syndrome (t&#x2009;=&#x2009;0); (III) persistence of myeloid dysplasia (indicated with an arrow) at t&#x2009;=&#x2009;6; (IV) appearance of a monocytosis (solid arrow) with excess of blasts (dashed arrow) when progression to CMML at t&#x2009;=&#x2009;6. <bold>b</bold> Blood monocyte counts and serum CRP levels at the indicated time points in patient #9. t&#x2009;=&#x2009;0 is first time the patient complained about symptoms worsening. The solid black arrow indicates the time of CMML diagnosis and the dashed arrow indicates when plasma was drawn for cytokine measurements. <bold>c</bold> IL-6 levels in plasma samples from patient #9, FMF patients and apparently healthy controls, as quantified by ELISA. <bold>d</bold> IL-18 levels in plasma samples from patient #9, FMF patients and apparently healthy controls, as quantified by ELISA</p></caption><graphic xlink:href="13023_2015_295_Fig1_HTML" id="MO1"/></fig></p>
      <p>Six months later (t&#x2009;=&#x2009;6), he presented with asthenia, fever and biological inflammatory syndrome although he took the same dose of colchicine. Serum amyloid A (SAA) as well as C-reactive protein (CRP) levels were elevated (226 and 20 mg/L respectively), and Hb was low (6.9 g/dL). Neither infection nor profound neoplasia was detected. He had no proteinuria, and salivary gland biopsy revealed no amyloidosis. Colchicine was increased to 1.5 mg per day, but because of occurrence of diarrhea &#x2013;a well-known side effect of colchicine therapy&#x2013;, the dose was finally maintained 1mg/day. During the following 3 months, his general status got worse: he lost 10 kg, fever and inflammatory syndrome persisted and required weekly red blood cell transfusions because of severe anemia (Hb&#x2009;=&#x2009;5.5 g/dL). His condition suddenly deteriorated, with elevated fever and fatigue. Further investigations showed a progressive increase in monocyte count above 1&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L with persistent anemia (Hb&#x2009;=&#x2009;6.8 g/dL) and severe inflammatory syndrome (SAA&#x2009;=&#x2009;327 mg/L; CRP 80 mg/L; Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1b</xref>). A new bone marrow smear confirmed CMML (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a</xref>, III&amp;IV). He died 6 months later from pneumonia in the context of persistent profound anemia (Hb&#x2009;=&#x2009;6.5 g/dL) and inflammation.</p>
      <p>FMF patients have been shown to display high plasma levels of proinflammatory cytokines [<xref ref-type="bibr" rid="CR9">9</xref>]. Their monocytes are spontaneously activated and secrete high levels of IL-1&#x3B2; [<xref ref-type="bibr" rid="CR10">10</xref>]. Cytokines implicated in the pathophysiology of FMF such as IL-1&#x3B2;, IL-18 and IL-6 are important for the regulation of immune and inflammatory responses. These cytokines are also involved in the pathophysiology of inflammatory anemia due to erythropoiesis blockade [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. It is therefore tempting to speculate that the transformation of refractory anemia into CMML, which resulted in an increased number of circulating monocytes in our FMF patient, could be responsible for the persistent inflammatory syndrome. In keeping with this hypothesis, the progressive monocytosis was accompanied by a progressive elevation of CRP levels (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1b</xref>) and persistence of refractory anemia.</p>
      <p>We measured the plasma levels of IL-1&#x3B2;, IL-18 and IL-6 in the patient [see Patients and Methods in Additional file <xref rid="MOESM1" ref-type="media">1</xref>], 10 months (t&#x2009;=&#x2009;10) after t&#x2009;=&#x2009;0, and compared them with cytokine levels from FMF patients carrying unambiguous <italic>MEFV</italic> mutations (n&#x2009;=&#x2009;8) [see Table S1 for genotype, inflammatory and clinical status of the FMF patients, in Additional file <xref rid="MOESM1" ref-type="media">1</xref>] and healthy controls. IL-6, a cytokine known to induce acute phase proteins, was not detected in the controls&#x2019; plasma but was present at a concentration of 64 pg/mL in the CMML patient and also easily detectable in 4 other FMF patients (3&#x2013;177 pg/mL), of whom 3 were under colchicine therapy (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1c</xref>). IL-1&#x3B2; is produced by monocytes and tissue macrophages as a precursor, which is then processed to its active form by the inflammasome, an intracellular multiprotein complex [<xref ref-type="bibr" rid="CR13">13</xref>]. IL-1&#x3B2; is mainly detected in supernatants of monocyte culture after stimulation with Toll-Like receptor agonists like lipopolysaccharide [<xref ref-type="bibr" rid="CR10">10</xref>]. Although <italic>ex-vivo</italic> studies demonstrated a major role of IL-1&#x3B2; in the pathogenesis of FMF, serum levels have been reported normal or even decreased in FMF patients [<xref ref-type="bibr" rid="CR14">14</xref>]. Accordingly, IL-1&#x3B2; was not detected in the patient&#x2019;s plasma, in controls, and in 6 out of the 8 FMF patients (data not shown). IL-18, which is also secreted by monocytes and regulated by inflammasome, was found at much higher levels in the patient&#x2019;s plasma (7647 pg/mL) than in other patients (187&#x2013;4527 pg/mL) or controls (172&#x2013;246 pg/mL) (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1d</xref>). As these cytokines are known to be involved in chronic inflammation in FMF [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], their presence could readily explain the uncontrolled inflammation seen in the patient.</p>
      <p>From a more general viewpoint, our study unveils the interplay between two different disorders involving the same target cells. More specifically, it suggests that in myelodysplasia with inflammatory manifestations [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], mutations in genes causing autoinflammatory syndromes, such as those found in <italic>MEFV</italic>, can be present and thus could be sought [<xref ref-type="bibr" rid="CR17">17</xref>]. In this context it is interesting to note that an allogenic bone marrow transplantation on a young patient who had congenital dyserythropoietic anemia and FMF was once reported to significantly improve/treat the FMF symptoms [<xref ref-type="bibr" rid="CR18">18</xref>] due to the hematopoietic involvement of the two disorders.</p>
      <p>Our data suggest that among elderly FMF patients, with CMML, a severe inflammatory syndrome may appear and has to be treated. CMML diagnosis should be confirmed by bone marrow aspiration; and cytotoxic chemotherapy and/or a demethylating agent should be considered in order to reduce monocytosis. This is even more important, as monocytosis is a key factor in the pathogenesis of FMF and the subsequent production of proinflammatory cytokines. In these rare cases of FMF or other autoinflammatory diseases combined with CMML, interleukin inhibitors (against IL-1, IL-6 or IL-18) alone or associated with a demethylating agent could represent a valuable therapeutic strategy to decrease a potentially fatal inflammatory syndrome.</p>
    </sec>
  </body>
  <back>
    <app-group>
      <app id="App1">
        <sec id="Sec2">
          <title>Additional file</title>
          <p>
            <media position="anchor" xlink:href="13023_2015_295_MOESM1_ESM.pdf" id="MOESM1">
              <label>Additional file 1:</label>
              <caption>
                <p>
<bold>Patients and Methods.</bold>
<bold>Table S1.</bold> Genotype, inflammatory and clinical status of the FMF patients. </p>
              </caption>
            </media>
          </p>
        </sec>
      </app>
    </app-group>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>FMF</term>
          <def>
            <p>Familial Mediterranean fever</p>
          </def>
        </def-item>
        <def-item>
          <term>CMML</term>
          <def>
            <p>Chronic myelomonocytic leukemia</p>
          </def>
        </def-item>
        <def-item>
          <term>CRP</term>
          <def>
            <p>C reactive protein</p>
          </def>
        </def-item>
        <def-item>
          <term>IL</term>
          <def>
            <p>Interleukin</p>
          </def>
        </def-item>
        <def-item>
          <term>SAA</term>
          <def>
            <p>Serum amyloid A</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>Fawaz Awad and Sophie Georgin-Lavialle contributed equally to this work.</p>
      </fn>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>Conception and design: FA, SGL, S-AK, OH, SA. Cytokine measurements: FA, S-AK. Provision of study materials: OH, SGL, GG, AB, KSS, AA, CD. Data collection and analysis: SGL, OH, FA, S-AK, SA. Manuscript writing: All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>Fawaz Awad (F.A) was supported from a grant from the French government and Alquds University, Palestine and from the &#x201C;<italic>Fondation pour la Recherche M&#xE9;dicale</italic>&#x201D; (FDT20130928419). We thank the Department Hospitalo-Universitaire - Inflammation Immunopathology - Biotherapy (DHU I2B) for supporting our work.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>French FMF Consortium</collab>
          </person-group>
          <article-title>A candidate gene for familial Mediterranean fever</article-title>
          <source>Nat Genet</source>
          <year>1997</year>
          <volume>17</volume>
          <fpage>25</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="doi">10.1038/ng0997-25</pub-id>
          <pub-id pub-id-type="pmid">9288094</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Consortium</surname>
              <given-names>TIF</given-names>
            </name>
          </person-group>
          <article-title>Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium</article-title>
          <source>Cell</source>
          <year>1997</year>
          <volume>90</volume>
          <fpage>797</fpage>
          <lpage>807</lpage>
          <pub-id pub-id-type="doi">10.1016/S0092-8674(00)80539-5</pub-id>
          <pub-id pub-id-type="pmid">9288758</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Centola</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Frucht</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Galon</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Aringer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Farrell</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kingma</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Horwitz</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Mansfield</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Holland</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>O&#x2019;Shea</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Rosenberg</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Malech</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Kastner</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
          <article-title>The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators</article-title>
          <source>Blood</source>
          <year>2000</year>
          <volume>95</volume>
          <fpage>3223</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="pmid">10807793</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cantarini</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Volpi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Galeazzi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Giani</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fanti</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lucherini</surname>
              <given-names>OM</given-names>
            </name>
            <name>
              <surname>Aglian&#xF2;</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Alessandrini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Giannini</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Magi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Greco</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Baldari</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Cimaz</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Colchicine myopathy and neuromyopathy: two cases with different characteristics</article-title>
          <source>J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis</source>
          <year>2010</year>
          <volume>16</volume>
          <fpage>229</fpage>
          <lpage>32</lpage>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Selmi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ceribelli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Naguwa</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Cantarini</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Shoenfeld</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Safety issues and concerns of new immunomodulators in rheumatology</article-title>
          <source>Expert Opin Drug Saf</source>
          <year>2015</year>
          <volume>14</volume>
          <fpage>389</fpage>
          <lpage>99</lpage>
          <pub-id pub-id-type="doi">10.1517/14740338.2015.993605</pub-id>
          <pub-id pub-id-type="pmid">25518908</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cantarini</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lopalco</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Caso</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Iannone</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lapadula</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Anelli</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Franceschini</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Menicacci</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Galeazzi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Selmi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rigante</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Beh&#xE7;et&#x2019;s disease</article-title>
          <source>Autoimmun Rev</source>
          <year>2015</year>
          <volume>14</volume>
          <fpage>1</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1016/j.autrev.2014.08.008</pub-id>
          <pub-id pub-id-type="pmid">25151975</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Itzkson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fenaux</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Solary</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?</article-title>
          <source>Best Pract Res Clin Haematol</source>
          <year>2013</year>
          <volume>26</volume>
          <fpage>387</fpage>
          <lpage>400</lpage>
          <pub-id pub-id-type="doi">10.1016/j.beha.2013.09.006</pub-id>
          <pub-id pub-id-type="pmid">24507815</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Patnaik</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Parikh</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Hanson</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Tefferi</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review</article-title>
          <source>Br J Haematol</source>
          <year>2014</year>
          <volume>165</volume>
          <fpage>273</fpage>
          <lpage>86</lpage>
          <pub-id pub-id-type="doi">10.1111/bjh.12756</pub-id>
          <pub-id pub-id-type="pmid">24467717</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ibrahim</surname>
              <given-names>J-N</given-names>
            </name>
            <name>
              <surname>Jounblat</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Delwail</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Abou-Ghoch</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Salem</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Chouery</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Megarbane</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Medlej-Hashim</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lecron</surname>
              <given-names>J-C</given-names>
            </name>
          </person-group>
          <article-title><italic>Ex vivo</italic> PBMC cytokine profile in familial Mediterranean fever patients: Involvement of IL-1&#x3B2;, IL-1&#x3B1; and Th17-associated cytokines and decrease of Th1 and Th2 cytokines</article-title>
          <source>Cytokine</source>
          <year>2014</year>
          <volume>69</volume>
          <fpage>248</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cyto.2014.06.012</pub-id>
          <pub-id pub-id-type="pmid">25025954</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Omenetti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Carta</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Delfino</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Martini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gattorno</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rubartelli</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Increased NLRP3-dependent interleukin 1&#x3B2; secretion in patients with familial Mediterranean fever: correlation with MEFV genotype</article-title>
          <source>Ann Rheum Dis</source>
          <year>2014</year>
          <volume>73</volume>
          <fpage>462</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1136/annrheumdis-2012-202774</pub-id>
          <pub-id pub-id-type="pmid">23505242</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Macdougall</surname>
              <given-names>IC</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
          <article-title>Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines</article-title>
          <source>Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc</source>
          <year>2002</year>
          <volume>17</volume>
          <issue>Suppl 11</issue>
          <fpage>39</fpage>
          <lpage>43</lpage>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maury</surname>
              <given-names>CPJ</given-names>
            </name>
            <name>
              <surname>Liljestr&#xF6;m</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Laiho</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tiitinen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kaarela</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hurme</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Anaemia of chronic disease in AA amyloidosis is associated with allele 2 of the interleukin-1beta-511 promoter gene and raised levels of interleukin-1beta and interleukin-18</article-title>
          <source>J Intern Med</source>
          <year>2004</year>
          <volume>256</volume>
          <fpage>145</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2796.2004.01353.x</pub-id>
          <pub-id pub-id-type="pmid">15257727</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martinon</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Burns</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tschopp</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta</article-title>
          <source>Mol Cell</source>
          <year>2002</year>
          <volume>10</volume>
          <fpage>417</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="doi">10.1016/S1097-2765(02)00599-3</pub-id>
          <pub-id pub-id-type="pmid">12191486</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gang</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Drenth</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Langevitz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Zemer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Brezniak</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Pras</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>van der Meer</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Livneh</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Activation of the cytokine network in familial Mediterranean fever</article-title>
          <source>J Rheumatol</source>
          <year>1999</year>
          <volume>26</volume>
          <fpage>890</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">10229412</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Braun</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fenaux</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence?</article-title>
          <source>Best Pract Res Clin Haematol</source>
          <year>2013</year>
          <volume>26</volume>
          <fpage>327</fpage>
          <lpage>36</lpage>
          <pub-id pub-id-type="doi">10.1016/j.beha.2013.09.003</pub-id>
          <pub-id pub-id-type="pmid">24507810</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mekinian</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Braun</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Decaux</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Falgarone</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Toussirot</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Raffray</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Omouri</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gombert</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>De Wazieres</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Buchdaul</surname>
              <given-names>A-L</given-names>
            </name>
            <name>
              <surname>Ziza</surname>
              <given-names>J-M</given-names>
            </name>
            <name>
              <surname>Launay</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Denis</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Madaule</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rose</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Grignano</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Fenaux</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fain</surname>
              <given-names>O</given-names>
            </name>
            <collab>Club Rhumatismes et Inflammation (CRI), Groupe Francophone des My&#xE9;lodysplasies (GFM), Soci&#xE9;t&#xE9; Nationale Fran&#xE7;aise de M&#xE9;decine Interne (SNFMI)</collab>
          </person-group>
          <article-title>Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases</article-title>
          <source>Medicine (Baltimore)</source>
          <year>2014</year>
          <volume>93</volume>
          <fpage>1</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="doi">10.1097/MD.0000000000000011</pub-id>
          <pub-id pub-id-type="pmid">24378738</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Horio</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Migita</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Sweet&#x2019;s syndrome in patients with MDS and MEFV mutations</article-title>
          <source>N Engl J Med</source>
          <year>2015</year>
          <volume>372</volume>
          <fpage>686</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMc1412998</pub-id>
          <pub-id pub-id-type="pmid">25671271</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Milledge</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Mansour</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Williamson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bennetts</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Roscioli</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Curtin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Christodoulou</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Allogeneic bone marrow transplantation: cure for familial Mediterranean fever</article-title>
          <source>Blood</source>
          <year>2002</year>
          <volume>100</volume>
          <fpage>774</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2002-02-0651</pub-id>
          <pub-id pub-id-type="pmid">12130485</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
